- Home
- / Dyne Therapeutics
Dyne Therapeutics
Stock Price
$32.4
2024-09-10
Market Capitalization
$3.3 B
2024-09-10
Dyne Therapeutics Summary
Company Summary
- Overview
- Dyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company develops a program that will focus on using antibody-oligo conjugates to block the repetitive DNA mutations that cause the disease myotonic dystrophy type 1.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Waltham, MA, US | view all locations
- Website
- https://www.dyne-tx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Oxana Beskrovnaya, Chief Scientific Officer
Molly White, Vice President, Global Head of Advocacy and Engagement
Susanna High, Chief Operating Officer
Dyne Therapeutics Financials
Summary Financials
- Net income (Q2, 2024)
- ($65.1M)
- Cash (Q2, 2024)
- $608.2M
- EBIT (Q2, 2024)
- ($72.0M)
- Enterprise value
- $2.8B